Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
retifanlimab + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Retifanlimab + carboplatin + paclitaxel** is a combination regimen consisting of retifanlimab-dlwr (a programmed death receptor-1 (PD-1) blocking monoclonal antibody), carboplatin (a platinum-based chemotherapeutic agent), and paclitaxel (a microtubule inhibitor). This combination is FDA-approved for first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). Retifanlimab blocks the PD-1 receptor on T-cells, thereby restoring immune surveillance and anti-tumor immune response. Carboplatin induces DNA crosslinking and inhibits DNA synthesis, leading to apoptosis in rapidly dividing cells. Paclitaxel disrupts microtubule function, inhibiting cellular mitosis. The regimen demonstrated improved progression-free and overall survival compared to carboplatin/paclitaxel alone in clinical trials[1][3][5][7].
- Brand names
- Zynyz
- Other names
- retifanlimab + carboplatin + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on retifanlimab + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on retifanlimab + carboplatin + paclitaxel.